{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:36:21Z","timestamp":1790775381187,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:00:00Z","timestamp":1553731200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81621064"],"award-info":[{"award-number":["81621064"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81702934"],"award-info":[{"award-number":["81702934"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2016-I2M-02-002"],"award-info":[{"award-number":["2016-I2M-02-002"]}]},{"name":"National Key R&D Plan","award":["2018ZX09711001-007-002"],"award-info":[{"award-number":["2018ZX09711001-007-002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Skeletal Muscle"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13395-019-0193-2","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T08:03:22Z","timestamp":1553760202000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["IMB0901 inhibits muscle atrophy induced by cancer cachexia through MSTN signaling pathway"],"prefix":"10.1186","volume":"9","author":[{"given":"Dong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinran","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijuan","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyi","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,28]]},"reference":[{"key":"193_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489\u201395.","journal-title":"Lancet Oncol"},{"key":"193_CR2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.biocel.2016.04.006","volume":"79","author":"J Aniort","year":"2016","unstructured":"Aniort J, Polge C, Claustre A, et al. Upregulation of MuRF1 and MAFbx participates to muscle wasting upon gentamicin-induced acute kidney injury. Int J Biochem Cell Biol. 2016;79:505\u201316.","journal-title":"Int J Biochem Cell Biol"},{"key":"193_CR3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.coph.2015.04.003","volume":"22","author":"JM Argiles","year":"2015","unstructured":"Argiles JM, Busquets S, Stemmler B, et al. Cachexia and sarcopenia: mechanisms and potential targets for intervention. Curr Opin Pharmacol. 2015;22:100\u20136.","journal-title":"Curr Opin Pharmacol"},{"key":"193_CR4","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1096\/fj.06-6604com","volume":"21","author":"JM Sacheck","year":"2007","unstructured":"Sacheck JM, Hyatt JP, Raffaello A, et al. Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J. 2007;21:140\u201355.","journal-title":"FASEB J"},{"key":"193_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13539-010-0002-6","volume":"1","author":"S Haehling von","year":"2010","unstructured":"von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2010;1:1\u20135.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"193_CR6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1056\/NEJMcibr1106880","volume":"365","author":"KC Fearon","year":"2011","unstructured":"Fearon KC. Cancer cachexia and fat-muscle physiology. N Engl J Med. 2011;365:565\u20137.","journal-title":"N Engl J Med"},{"key":"193_CR7","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/SPC.0000000000000012","volume":"7","author":"S Ali","year":"2013","unstructured":"Ali S, Chen JA, Garcia JM. Clinical development of ghrelin axis-derived molecules for cancer cachexia treatment. Curr Opin Support Palliat Care. 2013;7:368\u201375.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"Suppl 1","key":"193_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000229762","volume":"72","author":"O Schakman","year":"2009","unstructured":"Schakman O, Gilson H, Kalista S, et al. Mechanisms of muscle atrophy induced by glucocorticoids. Horm Res. 2009;72(Suppl 1):36\u201341.","journal-title":"Horm Res"},{"key":"193_CR9","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/bjc.1993.126","volume":"67","author":"KL Smith","year":"1993","unstructured":"Smith KL, Tisdale MJ. Increased protein degradation and decreased protein synthesis in skeletal muscle during cancer cachexia. Br J Cancer. 1993;67:680\u20135.","journal-title":"Br J Cancer"},{"key":"193_CR10","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1016\/j.biocel.2013.05.019","volume":"45","author":"HQ Han","year":"2013","unstructured":"Han HQ, Zhou X, Mitch WE, et al. Myostatin\/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol. 2013;45:2333\u201347.","journal-title":"Int J Biochem Cell Biol"},{"key":"193_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.semcdb.2015.11.002","volume":"54","author":"M Sandri","year":"2016","unstructured":"Sandri M. Protein breakdown in cancer cachexia. Semin Cell Dev Biol. 2016;54:11\u20139.","journal-title":"Semin Cell Dev Biol"},{"key":"193_CR12","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/j.biocel.2013.05.032","volume":"45","author":"N Johns","year":"2013","unstructured":"Johns N, Stephens NA, Fearon KC. Muscle wasting in cancer. Int J Biochem Cell Biol. 2013;45:2215\u201329.","journal-title":"Int J Biochem Cell Biol"},{"key":"193_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12885-016-2121-8","volume":"16","author":"TC Mueller","year":"2016","unstructured":"Mueller TC, Bachmann J, Prokopchuk O, et al. Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia--can findings from animal models be translated to humans? BMC Cancer. 2016;16:75.","journal-title":"BMC Cancer"},{"key":"193_CR14","doi-asserted-by":"publisher","first-page":"R674","DOI":"10.1152\/ajpregu.00104.2006","volume":"291","author":"P Costelli","year":"2006","unstructured":"Costelli P, Muscaritoli M, Bossola M, et al. IGF-1 is downregulated in experimental cancer cachexia. Am J Physiol Regul Integr Comp Physiol. 2006;291:R674\u201383.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"193_CR15","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/nm.3988","volume":"21","author":"DC Guttridge","year":"2015","unstructured":"Guttridge DC. A TGF-beta pathway associated with cancer cachexia. Nat Med. 2015;21:1248\u20139.","journal-title":"Nat Med"},{"key":"193_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/00075197-200405000-00004","volume":"7","author":"SM Roth","year":"2004","unstructured":"Roth SM, Walsh S. Myostatin: a therapeutic target for skeletal muscle wasting. Curr Opin Clin Nutr Metab Care. 2004;7:259\u201363.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"193_CR17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/387083a0","volume":"387","author":"AC McPherron","year":"1997","unstructured":"McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387:83\u201390.","journal-title":"Nature"},{"key":"193_CR18","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/jcp.10044","volume":"190","author":"JN Artaza","year":"2002","unstructured":"Artaza JN, Bhasin S, Mallidis C, et al. Endogenous expression and localization of myostatin and its relation to myosin heavy chain distribution in C2C12 skeletal muscle cells. J Cell Physiol. 2002;190:170\u20139.","journal-title":"J Cell Physiol"},{"key":"193_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.phrs.2015.05.010","volume":"99","author":"V Dutt","year":"2015","unstructured":"Dutt V, Gupta S, Dabur R, et al. Skeletal muscle atrophy: potential therapeutic agents and their mechanisms of action. Pharmacol Res. 2015;99:86\u2013100.","journal-title":"Pharmacol Res"},{"key":"193_CR20","doi-asserted-by":"publisher","first-page":"7344","DOI":"10.1158\/0008-5472.CAN-14-0057","volume":"74","author":"YS Gallot","year":"2014","unstructured":"Gallot YS, Durieux AC, Castells J, et al. Myostatin gene inactivation prevents skeletal muscle wasting in cancer. Cancer Res. 2014;74:7344\u201356.","journal-title":"Cancer Res"},{"key":"193_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","volume":"142","author":"X Zhou","year":"2010","unstructured":"Zhou X, Wang JL, Lu J, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142:531\u201343.","journal-title":"Cell"},{"key":"193_CR22","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/SPC.0000000000000013","volume":"7","author":"RC Smith","year":"2013","unstructured":"Smith RC, Lin BK. Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013;7:352\u201360.","journal-title":"Curr Opin Support Palliat Care"},{"key":"193_CR23","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/1087057113482585","volume":"18","author":"JN Cash","year":"2013","unstructured":"Cash JN, Angerman EB, Kirby RJ, et al. Development of a small-molecule screening method for inhibitors of cellular response to myostatin and activin A. J Biomol Screen. 2013;18:837\u201344.","journal-title":"J Biomol Screen"},{"key":"193_CR24","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/bph.13766","volume":"174","author":"M Ge","year":"2017","unstructured":"Ge M, Liu H, Zhang Y, et al. The anti-hepatic fibrosis effects of dihydrotanshinone I are mediated by disrupting the yes-associated protein and transcriptional enhancer factor D2 complex and stimulating autophagy. Br J Pharmacol. 2017;174:1147\u201360.","journal-title":"Br J Pharmacol"},{"key":"193_CR25","doi-asserted-by":"publisher","first-page":"6973","DOI":"10.1158\/1078-0432.CCR-09-1525","volume":"15","author":"BH Tan","year":"2009","unstructured":"Tan BH, Birdsell LA, Martin L, et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009;15:6973\u20139.","journal-title":"Clin Cancer Res"},{"key":"193_CR26","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00268-012-1581-5","volume":"36","author":"BS Miller","year":"2012","unstructured":"Miller BS, Ignatoski KM, Daignault S, et al. Worsening central sarcopenia and increasing intra-abdominal fat correlate with decreased survival in patients with adrenocortical carcinoma. World J Surg. 2012;36:1509\u201316.","journal-title":"World J Surg"},{"key":"193_CR27","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1007\/s00018-014-1689-x","volume":"71","author":"J Rodriguez","year":"2014","unstructured":"Rodriguez J, Vernus B, Chelh I, et al. Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways. Cell Mol Life Sci. 2014;71:4361\u201371.","journal-title":"Cell Mol Life Sci"},{"key":"193_CR28","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1158\/1535-7163.MCT-14-0681","volume":"14","author":"RC Smith","year":"2015","unstructured":"Smith RC, Cramer MS, Mitchell PJ, et al. Myostatin neutralization results in preservation of muscle mass and strength in preclinical models of tumor-induced muscle wasting. Mol Cancer Ther. 2015;14:1661\u201370.","journal-title":"Mol Cancer Ther"},{"key":"193_CR29","doi-asserted-by":"publisher","first-page":"C188","DOI":"10.1152\/ajpcell.00542.2005","volume":"292","author":"DL Allen","year":"2007","unstructured":"Allen DL, Unterman TG. Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors. Am J Physiol Cell Physiol. 2007;292:C188\u201399.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"Suppl 3","key":"193_CR30","first-page":"195","volume":"56","author":"M Budasz-Rwiderska","year":"2005","unstructured":"Budasz-Rwiderska M, Jank M, Motyl T. Transforming growth factor-beta1 upregulates myostatin expression in mouse C2C12 myoblasts. J Physiol Pharmacol. 2005;56(Suppl 3):195\u2013214.","journal-title":"J Physiol Pharmacol"},{"key":"193_CR31","doi-asserted-by":"publisher","first-page":"E1128","DOI":"10.1152\/ajpendo.2001.281.6.E1128","volume":"281","author":"K Ma","year":"2001","unstructured":"Ma K, Mallidis C, Artaza J, et al. Characterization of 5\u2032-regulatory region of human myostatin gene: regulation by dexamethasone in vitro. Am J Physiol Endocrinol Metab. 2001;281:E1128\u201336.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"193_CR32","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1186\/1471-2407-14-997","volume":"14","author":"SM Judge","year":"2014","unstructured":"Judge SM, Wu CL, Beharry AW, et al. Genome-wide identification of FoxO-dependent gene networks in skeletal muscle during C26 cancer cachexia. BMC Cancer. 2014;14:997.","journal-title":"BMC Cancer"},{"key":"193_CR33","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1096\/fj.12-225755","volume":"27","author":"T Shan","year":"2013","unstructured":"Shan T, Liang X, Bi P, et al. Myostatin knockout drives browning of white adipose tissue through activating the AMPK-PGC1alpha-Fndc5 pathway in muscle. FASEB J. 2013;27:1981\u20139.","journal-title":"FASEB J"},{"key":"193_CR34","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/jcsm.12265","volume":"9","author":"JJ Hulmi","year":"2018","unstructured":"Hulmi JJ, Nissinen TA, Rasanen M, et al. Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle. J Cachexia Sarcopenia Muscle. 2018;9:417\u201332.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"193_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/srep32695","volume":"6","author":"TA Nissinen","year":"2016","unstructured":"Nissinen TA, Degerman J, Rasanen M, et al. Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes. Sci Rep. 2016;6:32695.","journal-title":"Sci Rep"},{"key":"193_CR36","first-page":"26","volume":"46","author":"V Kesik","year":"2016","unstructured":"Kesik V, Honca T, Gulgun M, et al. Myostatin as a marker for doxorubicin induced cardiac damage. Ann Clin Lab Sci. 2016;46:26\u201331.","journal-title":"Ann Clin Lab Sci"},{"key":"193_CR37","doi-asserted-by":"publisher","first-page":"19976","DOI":"10.1074\/jbc.M115.638411","volume":"290","author":"DN Seto","year":"2015","unstructured":"Seto DN, Kandarian SC, Jackman RW. A key role for leukemia inhibitory factor in C26 cancer cachexia. J Biol Chem. 2015;290:19976\u201386.","journal-title":"J Biol Chem"},{"key":"193_CR38","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/jcsm.12331","volume":"9","author":"T Golan","year":"2018","unstructured":"Golan T, Geva R, Richards D, et al. LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial. J Cachexia Sarcopenia Muscle. 2018;9:871\u20139.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"193_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13395-017-0141-y","volume":"7","author":"M St Andre","year":"2017","unstructured":"St Andre M, Johnson M, Bansal PN, et al. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys. Skelet Muscle. 2017;7:25.","journal-title":"Skelet Muscle"}],"container-title":["Skeletal Muscle"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13395-019-0193-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13395-019-0193-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13395-019-0193-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T00:18:11Z","timestamp":1585268291000},"score":1,"resource":{"primary":{"URL":"https:\/\/skeletalmusclejournal.biomedcentral.com\/articles\/10.1186\/s13395-019-0193-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,28]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["193"],"URL":"https:\/\/doi.org\/10.1186\/s13395-019-0193-2","relation":{},"ISSN":["2044-5040"],"issn-type":[{"value":"2044-5040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,28]]},"assertion":[{"value":"8 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Care of the animals was conducted in accordance with Regulation on the Administration of Experimental Animals (2013 Revision) issued by the National Scientific and Technological Committee of People\u2019s Republic of China. The studies were performed at Laboratory animal center, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, an organization accredited by Beijing Municipal Science & Technology Commission. All of the animal experimental procedures were approved by the Ethical Committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"8"}}